Together, these data suggest that activation of the PI3K/AKT pathway by PI3KCA mutations or PTEN loss drives tumorigenesis in GC, potentially defining a new molecular segment for AKT-based targeted therapies. This evidence concerns the gene AKT1 and gastric cancer.